|
Feb 19
|
|
$1020
$1020
-0.0%
|
N/A
|
Finnhub News
|
— |
Finnhub - LLY
Eli Lilly Trial Wins And Gene Editing Progres...
|
|
Feb 18
|
|
$1020
$1020
-0.0%
|
N/A
|
Finnhub News
|
— |
Finnhub - LLY
Jim Cramer Discusses Eli Lilly (LLY) & Weight...
|
|
Feb 18
|
|
$1020
$1020
-0.0%
|
N/A
|
Finnhub News
|
— |
Finnhub - LLY
XPH’s 29% Run Looks Tempting, But The 5y Char...
|
|
Feb 18
|
|
$1020
$1020
-0.0%
|
N/A
|
Finnhub News
|
— |
Finnhub - LLY
Structure Therapeutics: The Dark Horse Has Ta...
|
|
Feb 18
|
|
$1020
$1020
-0.0%
|
N/A
|
Finnhub News
|
— |
Finnhub - LLY
Eli Lilly and Company (LLY) Gains as Medicare...
|
|
Feb 18
|
|
$1020
$1020
-0.0%
|
N/A
|
Finnhub News
|
— |
Finnhub - LLY
Will Tavalisse Continue to Drive Rigel Pharma...
|
|
Feb 18
|
|
$1020
$1020
-0.0%
|
LONG
|
Marty Makary
FDA Commissioner
|
Makary notes that GLP-1 shortages are ending and emphasizes that compounders should be getting APIs directly from the patent holders (Novo Nordisk and Eli Lilly) to "play by the rules." The regulatory crackdown on "grey market" compounders eliminates low-cost competition. As the FDA forces the market back toward approved products and authorized supply chains, volume and pricing power return to the IP owners. LONG as the regulatory moat is re-established. Continued supply chain constraints or political pressure on list prices. |
CNBC
FDA's Marty Makary: Everything should be over...
|
|
Feb 18
|
|
$1020
$1020
-0.0%
|
N/A
|
Finnhub News
|
— |
Finnhub - LLY
Eli Lilly Trumps Novo Nordisk In GLP-1 Race: ...
|
|
Feb 18
|
|
$1020
$1020
-0.0%
|
N/A
|
Finnhub News
|
— |
Finnhub - LLY
Can LLY's Next-Gen Obesity Pipeline Sustain G...
|
|
Feb 18
|
|
$1020
$1020
-0.0%
|
N/A
|
Finnhub News
|
— |
Finnhub - LLY
Lilly's Taltz (ixekizumab) and Zepbound (tirz...
|
|
Feb 18
|
|
$1020
$1020
-0.0%
|
N/A
|
Finnhub News
|
— |
Finnhub - LLY
Pfizer: Recovery Isn't Over, Battered Valuati...
|
|
Feb 18
|
|
$1020
$1020
-0.0%
|
N/A
|
Finnhub News
|
— |
Finnhub - LLY
Lilly to pay CSL $100M to license monoclonal ...
|
|
Feb 18
|
|
$1020
$1020
-0.0%
|
N/A
|
Finnhub News
|
— |
Finnhub - LLY
An Alzheimer’s startup emerges with $175M in ...
|
|
Feb 18
|
|
$1020
$1020
-0.0%
|
N/A
|
Finnhub News
|
— |
Finnhub - LLY
Eli Lilly's TOGETHER-PsO Open-label Phase 3B ...
|
|
Feb 18
|
|
$1020
$1020
-0.0%
|
N/A
|
Finnhub News
|
— |
Finnhub - LLY
CSL Enters Into An Exclusive Licensing Agreem...
|
|
Feb 17
|
|
$1036
$1020
-1.5%
|
N/A
|
Finnhub News
|
— |
Finnhub - LLY
Eli Lilly Preps Oral Weight-Loss Launch
|
|
Feb 17
|
|
$1036
$1020
-1.5%
|
N/A
|
Finnhub News
|
— |
Finnhub - LLY
Eli Lilly Reports Phase 3 Win for Retevmo in ...
|
|
Feb 17
|
|
$1036
$1020
-1.5%
|
N/A
|
Finnhub News
|
— |
Finnhub - LLY
Agios Stock Down 16% in a Year as Fund Cuts S...
|
|
Feb 17
|
|
$1036
$1020
-1.5%
|
N/A
|
Finnhub News
|
— |
Finnhub - LLY
Cogent Biosciences Stock Soars 346% in a Year...
|
|
Feb 17
|
|
$1036
$1020
-1.5%
|
N/A
|
Finnhub News
|
— |
Finnhub - LLY
Structure Therapeutics Stock Up 187% in One Y...
|
|
Feb 17
|
|
$1036
$1020
-1.5%
|
N/A
|
Finnhub News
|
— |
Finnhub - LLY
Kymera Therapeutics Stock Up 120% in 1 Year a...
|
|
Feb 17
|
|
$1036
$1020
-1.5%
|
N/A
|
Finnhub News
|
— |
Finnhub - LLY
1 Reason I'd Buy Eli Lilly Stock and Never Se...
|
|
Feb 17
|
|
$1036
$1020
-1.5%
|
N/A
|
Finnhub News
|
— |
Finnhub - LLY
Eli Lilly Advances Gene Editing And Lung Canc...
|
|
Feb 17
|
|
$1036
$1020
-1.5%
|
N/A
|
Finnhub News
|
— |
Finnhub - LLY
Eli Lilly Stock Rises as $1.5 Billion Weight-...
|
|
Feb 17
|
|
$1036
$1020
-1.5%
|
N/A
|
Finnhub News
|
— |
Finnhub - LLY
Eli Lilly Targets India as Global Export Hub ...
|
|
Feb 17
|
|
$1036
$1020
-1.5%
|
N/A
|
Finnhub News
|
— |
Finnhub - LLY
Scribe Therapeutics Achieves Second Success M...
|
|
Feb 17
|
|
$1036
$1020
-1.5%
|
N/A
|
Finnhub News
|
— |
Finnhub - LLY
Novo Nordisk: The Possible Upside
|
|
Feb 17
|
|
$1036
$1020
-1.5%
|
N/A
|
Finnhub News
|
— |
Finnhub - LLY
Reported Earlier" 'Lilly targets India as glo...
|
|
Feb 17
|
|
$1036
$1020
-1.5%
|
N/A
|
Finnhub News
|
— |
Finnhub - LLY
Lilly targets India as global export hub amid...
|
|
Feb 17
|
|
$1036
$1020
-1.5%
|
N/A
|
Finnhub News
|
— |
Finnhub - LLY
Eli Lilly & Co (NYSE:LLY) Combines Explosive ...
|
|
Feb 17
|
|
$1036
$1020
-1.5%
|
N/A
|
Finnhub News
|
— |
Finnhub - LLY
Eli Lilly's Experimental Cancer Drug Cuts Rec...
|
|
Feb 17
|
|
$1036
$1020
-1.5%
|
N/A
|
Finnhub News
|
— |
Finnhub - LLY
Eli Lilly (LLY) Valuation Check After Positiv...
|
|
Feb 17
|
|
$1036
$1020
-1.5%
|
N/A
|
Finnhub News
|
— |
Finnhub - LLY
Reported Monday, Lilly Reports Retevmo Event-...
|
|
Feb 17
|
|
$1036
$1020
-1.5%
|
N/A
|
Finnhub News
|
— |
Finnhub - LLY
Reported Monday, Eli Lilly Joins USOPC As Pre...
|
|
Feb 16
|
|
$1040
$1020
-1.9%
|
N/A
|
Finnhub News
|
— |
Finnhub - LLY
Novo Nordisk's New Diabetes Drug Outshines Oz...
|
|
Feb 16
|
|
$1040
$1020
-1.9%
|
N/A
|
Finnhub News
|
— |
Finnhub - LLY
Why Eli Lilly’s $1 Billion AI Bet Could Resha...
|
|
Feb 16
|
|
$1040
$1020
-1.9%
|
N/A
|
Finnhub News
|
— |
Finnhub - LLY
Eli Lilly builds orforglipron cache to avoid ...
|
|
Feb 16
|
|
$1040
$1020
-1.9%
|
N/A
|
Finnhub News
|
— |
Finnhub - LLY
NVO Crashes 21% in a Month: Is This an Indica...
|
|
Feb 16
|
|
$1040
$1020
-1.9%
|
N/A
|
Finnhub News
|
— |
Finnhub - LLY
Lilly to participate in TD Cowen's 46th Annua...
|
|
Feb 16
|
|
$1040
$1020
-1.9%
|
N/A
|
Finnhub News
|
— |
Finnhub - LLY
How Investors Are Reacting To Eli Lilly (LLY)...
|
|
Feb 16
|
|
$1040
$1020
-1.9%
|
N/A
|
Finnhub News
|
— |
Finnhub - LLY
RIGL Stock Rises 59% in a Year: Time to Buy, ...
|
|
Feb 16
|
|
$1040
$1020
-1.9%
|
N/A
|
Finnhub News
|
— |
Finnhub - LLY
Eli Lilly Expands Beyond GLP-1 With RNA Cance...
|
|
Feb 16
|
|
$1040
$1020
-1.9%
|
N/A
|
Finnhub News
|
— |
Finnhub - LLY
AI is disrupting drug discovery faster than e...
|
|
Feb 16
|
|
$1040
$1020
-1.9%
|
N/A
|
Finnhub News
|
— |
Finnhub - LLY
USOPC Announces the Team USA Athlete Recovery...
|
|
Feb 16
|
|
$1040
$1020
-1.9%
|
N/A
|
Finnhub News
|
— |
Finnhub - LLY
Lilly's Retevmo (selpercatinib) delivers subs...
|
|
Feb 16
|
|
$1040
$1020
-1.9%
|
N/A
|
Finnhub News
|
— |
Finnhub - LLY
Zura Bio Highlights Key Phase 2 Tibulizumab R...
|
|
Feb 16
|
|
$1040
$1020
-1.9%
|
N/A
|
Finnhub News
|
— |
Finnhub - LLY
Theranostics earmarked as “the future” of rad...
|
|
Feb 15
|
|
$1040
$1020
-1.9%
|
N/A
|
Finnhub News
|
— |
Finnhub - LLY
Forget AI Stocks: This Pharma Giant Is Using ...
|
|
Feb 15
|
|
$1040
$1020
-1.9%
|
N/A
|
Finnhub News
|
— |
Finnhub - LLY
Beijing Could Focus on the Shopper in the Yea...
|
|
Feb 14
|
|
$1040
$1020
-1.9%
|
LONG
|
Finnhub News
|
Eli Lilly's strategic expansion into new therapeutic areas and technology partnerships signals future growth and innovation. |
Finnhub - LLY
Eli Lilly Expands Beyond GLP 1s With Orna Dea...
|